Document:

EX-10.2

 Exhibit 10.2 

ONCOLOGIC, INC. 2000 LONG-TERM INCENTIVE PLAN 

SUMMARY OF STOCK OPTION GRANT 

You have been granted the option to purchase shares of Common Stock of Oncologic, Inc., a California corporation
(“Oncologic”), on the terms and conditions set forth below and in accordance with the Stock Option Award Agreement (the “Agreement”) to which this Summary of Stock Option Grant is attached and the Oncologic, Inc. 2000 Long-Term
Incentive Plan (the “Plan”): 
  

			
	 Optionee Name:
	  	  

		
	 Number of Option Shares Granted:
	  	  

		
	 Type of Option (check one):
	  	  ̈  Incentive Stock Option

		  	  ̈  Nonqualified Stock Option

		
	 Effective Date:
	  	  

		
	 Exercise Price per Share:
	  	  

		
	 Vesting Commencement Date:
	  	  

		
	 Vesting Schedule:
	  	 This Option may be exercised with respect to 1/48th of the total number of option shares granted (if a
fractional number, then the next lower whole number) on the first day of each month after the Vesting Commencement Date if the Optionee is in the continuous service of Oncologic or an Affiliate until each such monthly date.

 By your signature and the signature of Oncologic’s representative below, you and
Oncologic agree that the Option is granted under and governed by the terms of the Agreement and the Plan. 
  

									
	 OPTIONEE:
	 		 	 Oncologic, Inc.

				
	  
	 		 	 By:
	 	  

	 (Signature of Optionee)
	 		 		 	 Name
	 	  

		 		 		 	 Title: 
	 	  

 ONCOLOGIC, INC. 2000 LONG-TERM INCENTIVE PLAN 

CONSENT OF OPTIONEE’S SPOUSE 

I have reviewed the Stock Option Award Agreement, the Summary of Stock Option Grant, and the Oncologic, Inc. 2000 Long-Term
Incentive Plan and agree to and accept all of the terms set forth therein to the extent of any interest I may now have or may have in the future pursuant to the grant of the Option described therein to my spouse. 

 

	
	 OPTIONEE’S SPOUSE:

	
	  

	 Signature of Optionee’s Spouse, if any

 ONCOLOGIC, INC. 

STOCK OPTION AWARD AGREEMENT 

THIS AGREEMENT is made as of the Effective Date (as set forth on the Summary of Stock Option Grant) between Oncologic, Inc., a
California corporation (“Oncologic”), and Optionee pursuant to the Oncologic, Inc. 2000 Long-Term Incentive Plan (the “Plan”). 

WHEREAS, the Board of Directors of Oncologic (the “Board”) or a Committee designated by the Board has authority to
grant Options under the Plan to employees, outside directors and consultants of Oncologic and its Affiliates; and 

WHEREAS, the Board or the Committee, as appropriate, has determined to award Optionee the Option described in this Agreement;

 NOW, THEREFORE, Oncologic and Optionee agree as follows: 

1. Effect of Plan and Authority of Board or Committee. This Agreement and the Option granted hereunder are subject to
the Plan, which is incorporated herein by reference. The Board or the Committee is authorized to make all determinations and interpretations with respect to matters arising under the Plan, this Agreement and the Option granted hereunder. Capitalized
terms used and not otherwise defined herein have the respective meanings given them in the Plan or in the Summary of Stock Option Grant, which is attached hereto and incorporated herein by this reference for all purposes. 

2. Grant of Option. On the terms and conditions set forth in this Agreement, the Summary of Stock Option Grant and the
Plan, as of the Effective Date, Oncologic hereby grants to Optionee the option to purchase the number of shares of Common Stock set forth on the Summary of Stock Option Grant at the Exercise Price per share set forth on the Summary of Stock Option
Grant (the “Option”). The Option is intended to be an Incentive Stock Option or a Nonqualified Stock Option, as provided in the Summary of Stock Option Grant. If the Option is intended to be an Incentive Stock Option, it is agreed that the
exercise price is at least 100% of the Fair Market Value of a share of Common Stock on the Effective Date (110% of Fair Market Value if Optionee owns stock possessing more than 10% of the total combined voting power of all classes of stock of
Oncologic or an Affiliate, within the meaning of Section 422(b)(6) of the Code). 
 3. Exercisability and
Restrictions. 
 (a) Vesting. Subject to the provisions of Section 3(b), this Option may be
exercised in accordance with the Vesting Schedule set forth on the Summary of Stock Option Grant. Each installment shall be exercisable, as to all or part of the shares covered by the installment, at any time or times after the respective vesting
date for such installment and until the expiration or termination of the Option. 
 (b) Stock Purchase
Agreement. Upon the exercise of all or any portion of the Option, Optionee shall be required, as a condition to such exercise, to execute Oncologic’s Stock Purchase Agreement in substantially the same form delivered to Optionee as of the date
hereof (the “Stock Purchase Agreement”). 
 (c) Right of First Refusal/Repurchase. All shares of
Common Stock acquired by Optionee pursuant to the exercise of this Option shall be subject to the following restrictions: 

 (i) Right of First Refusal. In the event that Optionee desires to
accept a bona fide offer made in good faith by a third party with respect to the sale, assignment, transfer or other disposition of all or a part of the shares of Common Stock purchased pursuant to the exercise of this Option such sale, assignment,
transfer or other disposition shall be made pursuant to the terms and or the conditions set forth in the Stock Purchase Agreement. 

(ii) Right to Repurchase. In the event of Optionee’s termination of employment or service, the relative
rights of Oncologic and Optionee shall be governed by the Stock Purchase Agreement. 
 4. Term. 

(a) Term of Option. This Option may not be exercised after the expiration of 10 years from the Effective Date
(five years from the Effective Date if Optionee owns stock possessing more than 10% of the total combined voting power of all classes of stock of Oncologic or an Affiliate, within the meaning of Section 422(b)(6) of the Code). 

(b) Early Termination. Except as provided below, this Option may not be exercised unless Optionee shall have
been in the continuous employ or service of Oncologic or an Affiliate from the Effective Date to the date of exercise of the Option. This Option may be exercised after the date of Optionee’s termination of employment or service with Oncologic
or an Affiliate only in accordance with the following: 
 (i) In the event of Optionee’s termination of
employment or service on account of death or permanent or total disability (within the meaning of Section 22(e)(3) of the Code), this Option may be exercised, to the extent then vested, for up to one year from the date of such termination of
employment or service, unless the Option, by its terms, expires earlier. 
 (ii) In the event of
Optionee’s termination of employment or service for any reason other than the reasons set forth in subparagraphs (i) and (iii) of this Section 4(b), this Option may be exercised, to the extent then vested, for up to three months
from the date of such termination of employment or service, unless the Option, by its terms, expires earlier. 

(iii) Notwithstanding subparagraphs (i) and (ii) above, if Optionee’s termination of employment
or service by reason of (i) Optionee’s fraud or dishonesty, (ii) any unauthorized use or disclosure by Optionee of any confidential information or trade secrets of the Company, (iii) any unauthorized disclosure by Optionee of the
amount of Options provided hereunder, (iv) the performance by Optionee of other acts detrimental to the Company, or (v) without limiting the foregoing, “cause” as defined in any then-applicable employment or service agreement
between the Company and Optionee, then in any such case this Option shall be immediately forfeited to Oncologic and no additional exercise period shall be allowed, regardless of the vested status of the Option, unless otherwise determined by the
Board in its sole discretion. 
 5. Manner of Exercise and Payment. This Option shall be exercised by the delivery of
a written notice of exercise in a form prescribed by the Board or the Committee to Oncologic, setting forth the number of shares of Common Stock with respect to which the Option is to be exercised, accompanied

  
 -2- 

 
by full payment for such shares. The purchase price for such shares shall be payable to Oncologic in the manner specified in Section 7.5 of the Plan. 

6. Withholding Tax. Promptly after demand by Oncologic, and at its direction, Optionee shall pay to Oncologic or the
appropriate Affiliate an amount equal to the applicable withholding taxes due in connection with the exercise of the Option. Pursuant to Section 14.5 of the Plan, such withholding taxes may be paid in cash or, subject to the further provisions
of this Section 6 of this Agreement, in whole or in part, by having Oncologic withhold from the shares of Common Stock otherwise issuable upon exercise of the Option a number of shares of Common Stock having a value equal to the amount of such
withholding taxes or by delivering to Oncologic or the appropriate Affiliate a number of issued and outstanding shares of Common Stock (excluding restricted shares still subject to a risk of forfeiture) having a value equal to the amount of such
withholding taxes. The value of any shares of Common Stock so withheld by or delivered to Oncologic or the appropriate Affiliate shall be based on the Fair Market Value (as defined in the Plan) of such shares on the date on which the tax withholding
is to be made. Optionee shall pay to Oncologic or the appropriate Affiliate in cash the amount, if any, by which the amount of such withholding taxes exceeds the value of the shares of Common Stock so withheld or delivered. An election by Optionee
to have shares withheld or to deliver shares to pay withholding taxes (an “Election”) must be made at or prior to the time of exercise of the Option. All Elections shall be made in the same manner as is required for the exercise of the
Option and shall be made on a form approved by Oncologic. 
 7. Delivery of Shares. Delivery of the certificates
representing the shares of Common Stock purchased upon exercise of this Option shall be made promptly after receipt of notice of exercise and full payment of the exercise price and any required withholding taxes. If Oncologic so elects, its
obligation to deliver shares of Common Stock upon the exercise of this Option shall be conditioned upon its receipt from the person exercising this Option of an executed investment letter, in form and content satisfactory to Oncologic and its legal
counsel, evidencing the investment intent of such person and such other matters as Oncologic • may reasonably require. If Oncologic so elects, the certificate or certificates representing the shares of Common Stock issued upon exercise of this
Option shall bear a legend in substantially the following form: 
 THE ISSUANCE OF THE COMMON STOCK EVIDENCED BY THIS
CERTIFICATE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS AND SUCH COMMON STOCK MAY NOT BE SOLD OR OTHERWISE TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS FIRST REGISTERED THEREUNDER OR UNLESS ONCOLOGIC,
INC. RECEIVES A WRITTEN OPINION OF COUNSEL, WHICH OPINION AND COUNSEL ARE ACCEPTABLE TO ONCOLOGIC, INC., TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED. 

In addition, each certificate representing shares of Common Stock issued pursuant to the Option shall bear a legend in substantially the
following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ISSUED PURSUANT TO THE TERMS OF THE LONG-TERM
INCENTIVE PLAN OF ONCOLOGIC, INC. AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE ENCUMBERED OR DISPOSED OF EXCEPT AS SET FORTH IN THE TERMS OF AN AGREEMENT ENTERED INTO BETWEEN THE REGISTERED OWNER HEREOF AND ONCOLOGIC, INC. A COPY
OF SUCH PLAN AND AGREEMENT ARE ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ONCOLOGIC, INC. 

  
 -3- 

 8. Nonassignability. The Option granted hereunder may not be sold,
transferred, pledged, exchanged, hypothecated or otherwise disposed of, other than by will or pursuant to the applicable laws of descent and distribution. In the case of the death of Optionee or other person entitled to exercise the Option,
Oncologic may require, as a condition to the transfer of the Option by will or pursuant to the laws of descent and distribution or the exercise thereof, that the person entitled to exercise the Option execute and deliver to Oncologic such
instruments and documents as may be reasonably requested by Oncologic to evidence and confirm such person’s right and title to the Option. 

9. Notices. All notices between the parties hereto shall be in writing. Notices to Optionee shall be given to
Optionee’s address as contained in Oncologic’s records. Notices to Oncologic shall be addressed to LTIP Administrator at the principal executive offices of Oncologic as set forth in Section 14.7 of the Plan. 

10. Relationship With Contract of Employment or Other Contract Services. 

(a) The grant of an Option does not form part of Optionee’s entitlement to remuneration or benefit
pursuant to his contract of employment, if any, nor does the existence of a contract of employment between any person and Oncologic or an Affiliate give such person any right or entitlement to have an Option granted to him or any expectation that an
Option might be granted to him whether subject to any conditions or at all. 
 (b) The rights and obligations
of Optionee under the terms of his contract of employment or other contract or agreement for services with Oncologic or an Affiliate, if any, shall not be affected by the grant of an Option. 

(c) The rights granted to Optionee upon the grant of an Option shall not afford Optionee any rights or
additional rights to compensation or damages in consequence of the loss or termination of his office, employment or service with Oncologic or an Affiliate for any reason whatsoever. 

(d) Optionee shall not be entitled to any compensation or damages for any loss or potential loss which he may
suffer by reason of being or becoming unable to exercise an Option in consequence of the loss or termination of his office, employment or service with Oncologic or an Affiliate for any reason (including, without limitation, any breach of contract by
Oncologic or an Affiliate) or in any other circumstances whatsoever. 
 11. Governing Law. This Agreement shall be
governed by and construed in accordance with the internal laws (and not the principles relating to conflicts of laws) of the State of California, except as superseded by applicable federal law. 

  
 -4- 

 ONCOLOGIC, INC. 

STOCK PURCHASE AGREEMENT 

This AGREEMENT is made this      day of
                , 200     by and between Oncologic, Inc., a California corporation (the “Corporation”), and
                            , Optionee under the Oncologic 2000 Long-Term Incentive Plan (the
“Plan”). 
 All capitalized terms not otherwise defined in this Agreement shall have the meaning assigned
to them in the Plan. 
  

	 A.
	 EXERCISE OF OPTION 

1. Exercise. Optionee hereby purchases
                 shares of Common Stock (the “Purchased Shares”) pursuant to that certain option (the “Option”) granted Optionee on
                     (the “Effective Date”) to purchase up to
                 shares of Common Stock (the “Option Shares”) under the Plan at the exercise price of
                 per share (the “Exercise Price”). 

2. Payment. Concurrently with the delivery of this Agreement to the Corporation, Optionee shall pay the
Exercise Price for the Purchased Shares in accordance with the provisions of Optionee’s Award Agreement covering the Option and the Plan and shall deliver whatever additional documents may be required by the Award Agreement covering the Option
and the Plan as a condition for exercise, together with a duly-executed blank Assignment Separate from Certificate (in the form attached hereto as Exhibit I) with respect to the Purchased Shares. 

3. Stockholder Rights. Until such time as the Corporation exercises the First Refusal Right, Optionee (or
any successor in interest) shall have all the rights of a stockholder (including voting, dividend and liquidation rights) with respect to the Purchased Shares, subject, however, to the transfer restrictions of Articles B and C. 

 

	 B.
	 SECURITIES LAW COMPLIANCE 

1. Restricted Securities. The Purchased Shares have not been registered under the 1933 Act and are being
issued to Optionee in reliance upon the exemption from such registration provided by SEC Rule 701 for stock issuances under compensatory benefit plans such as the Plan. Optionee hereby confirms that Optionee has been informed that the Purchased
Shares are restricted securities under the 1933 Act and may not be resold or transferred unless the Purchased Shares are first registered under the Federal securities laws or unless an exemption from such registration is available. Accordingly,
Optionee hereby acknowledges that Optionee is prepared to hold the Purchased Shares for an indefinite period and that Optionee is aware that SEC Rule 144 issued under the 1933 Act which exempts certain resales of unrestricted securities is not
presently available to exempt the resale of the Purchased Shares from the registration requirements of the 1933 Act. 

2. Representations and Warranties of Optionee. Optionee hereby represents and warrants that: 

  
 -1- 

 (i) The Purchased Shares are being acquired for investment
purposes only for the Optionee’s own account, and not as a nominee or agent, and not with a view to the resale or distribution of all or any part of the Purchased Shares. Optionee is prepared to hold the Purchased Shares for an indefinite
period and has no present intention of selling, granting any participation in, or otherwise distributing any of the Purchased Shares. Optionee does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or
grant a participating interest in, any of the Purchased Shares. 
 (ii) Optionee has been furnished with, and
has had access to, such information as he considers necessary or appropriate for deciding whether to invest in the Purchased Shares, and Optionee has had an opportunity to ask questions and receive answers from the Corporation regarding the terms
and conditions of the issuance of the Purchased Shares. 
 (iii) Optionee is able to fend for him or herself
in the transactions contemplated by this Agreement, can bear the economic risk of investment in the Purchased Shares and has such knowledge and experience in financial or business matters to be capable of evaluating the merits and risks of the
investment in the Purchased Shares. 
 3. Restrictions on Disposition of Purchased Shares. Optionee
shall make no disposition of the Purchased Shares — other than: (i) a gratuitous transfer of the Purchased Shares, provided, and only if, Optionee obtains the Corporation’s prior written consent to such transfer, (ii) a transfer
of title to the Purchased Shares effected pursuant to Optionee’s will or the laws of intestate succession following Optionee’s death or (iii) a transfer to the Corporation in pledge as security for any purchase-money indebtedness
incurred by Optionee in connection with the acquisition of the Purchased Shares (as applicable, a “Permitted Transfer”) — unless and until there is compliance with all of the following requirements: 

(i) Optionee shall have provided the Corporation with a written summary of the terms and conditions of the
proposed disposition. 
 (ii) Optionee shall have complied with all requirements of this Agreement applicable
to the disposition of the Purchased Shares. 
 (iii) Optionee shall have provided the Corporation with
written assurances (which may include an opinion of legal counsel), in form and substance satisfactory to the Corporation, that (a) the proposed disposition does not require registration of the Purchased Shares under the 1933 Act or
(b) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including Rule 144) has been taken. 

The Corporation shall not be required (i) to transfer on its books any Purchased Shares which have been sold or
transferred in violation of the provisions of this Agreement or (ii) to treat as the owner of the Purchased Shares, or otherwise to accord voting, dividend or liquidation rights 

  
 -2- 

 
to, any transferee to whom the Purchased Shares have been transferred in contravention of this Agreement. 

4. Restrictive Legends. The stock certificates for the Purchased Shares shall be endorsed with one or
more of the following restrictive legends: 
 “The shares represented by this certificate have
not been registered under the Securities Act of 1933. The shares may not be sold or offered for sale in the absence of (a) an effective registration statement for the shares under such Act, (b) a “no action” letter of the
Securities and Exchange Commission with respect to such sale or offer or (c) satisfactory assurances to the Corporation that registration under such Act is not required with respect to such sale or offer.” 

“The shares represented by this certificate are subject to certain rights of first refusal granted to the
Corporation and accordingly may not be sold, assigned, transferred, encumbered, or in any manner disposed of except in conformity with the terms of a written agreement dated
                    , 200     between the Corporation and the registered holder of the shares (or the predecessor
in interest to the shares). A copy of such agreement is maintained at the Corporation’s principal corporate offices.” 
  

	 C.
	 TRANSFER RESTRICTIONS 

1. Restriction on Transfer. Purchased Shares shall not be transferred, assigned, encumbered or otherwise
disposed of in contravention of the First Refusal Right or the Market Stand-Off. 
 2. Transferee
Obligations. Each person (other than the Corporation) to whom the Purchased Shares are transferred by means of a Permitted Transfer must, as a condition precedent to the validity of such transfer, acknowledge in writing to the Corporation
that such person is bound by the provisions of this Agreement and that the transferred shares are subject to (1) the First Refusal Right and (ii) the Market Stand-Off, to the same extent such shares would be so subject if retained by
Optionee. 
 3. Market Stand-Off. 

(a) In connection with any underwritten public offering by the Corporation of its equity securities pursuant to
an effective registration statement filed under the 1933 Act, including the Corporation’s initial public offering, owner shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise
dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to, any Purchased Shares without the prior written consent of the Corporation or its underwriters. Such restriction (the “Market
Stand-Off) shall be in effect for such period of time from and after the effective date of the final prospectus for the offering as may be requested by the Corporation or such underwriters. In no event, however, shall such period exceed one hundred
eighty (180) days and the Market Stand-Off shall in all events terminate two (2) years after the effective date of the Corporation’s initial public offering. 

  
 -3- 

 (b) Owner shall be subject to the Market Stand-Off provided and
only if the officers and directors of the Corporation are also subject to similar restrictions. 
 (c) Any
new, substituted or additional securities that are distributed with respect to the Purchased Shares shall be immediately subject to the Market Stand-Off, to the same extent the Purchased Shares are at such time covered by such provisions. 

(d) In order to enforce the Market Stand-Off, the Corporation may impose stop-transfer instructions with
respect to the Purchased Shares until the end of the applicable stand-off period. 
  

	 D.
	 RIGHT OF FIRST REFUSAL 

1. Grant. The Corporation is hereby granted the right of first refusal (the “First Refusal
Right”), exercisable in connection with any proposed transfer of the Purchased Shares. For purposes of this Article D, the term “transfer” shall include any sale, assignment, pledge, encumbrance or other disposition of the Purchased
Shares intended to be made, but shall not include any Permitted Transfer. 
 2. Notice of Intended
Disposition. In the event any owner of vested Purchased Shares desires to accept a bona fide third-party offer for the transfer of any or all of such shares (the Purchased Shares subject to such offer to be hereinafter referred to as the
“Target Shares”), such owner shall promptly (i) deliver to the Corporation written notice (the “Disposition Notice”) of the terms of the offer, including the purchase price and the identity of the third-party offeror, and
(ii) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the provisions set forth in Articles B and C. 

3. Exercise of the First Refusal Right. The Corporation shall, for a period of twenty five (25) days
following receipt of the Disposition Notice, have the right to repurchase any or all of the Target Shares subject to the Disposition Notice upon the same terms as those specified therein. Such right shall be exercisable by delivery of written notice
(the “Exercise Notice”) to the owner prior to the expiration of the twenty-five (25)-day exercise period. If such right is exercised with respect to all the Target Shares, then the Corporation shall effect the repurchase of such shares,
including payment of the purchase price, not more than five (5) business days after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Corporation. 

Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of
indebtedness, the Corporation shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If owner and the Corporation cannot agree on such cash value within ten (10) days after the
Corporation’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of recognized standing selected by owner and the Corporation or, if they cannot agree on an appraiser within twenty (20) days after the
Corporation’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such
value. The cost of such appraisal shall be shared equally by owner and the Corporation. The closing shall then be held on the later of (i) the fifth (5th) 

  
 -4- 

 
business day following delivery of the Exercise Notice or (ii) the fifth (5th) business day after such valuation shall have been made. 

4. Non-Exercise of the First Refusal Right. In the event the Exercise Notice is not given to owner prior
to the expiration of the twenty-five (25)-day exercise period, owner shall have a period of thirty (30) days thereafter in which to sell or otherwise dispose of the Target Shares to the third-party offeror identified in the Disposition Notice
upon terms (including the purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided, however, that any such sale or disposition must not be effected in contravention of the
provisions of Articles B and C. The third-party offeror shall acquire the Target Shares free and clear of the First Refusal Right, but the acquired shares shall remain subject to the provisions of Article B and Paragraph C.3. In the event owner does
not effect such sale or disposition of the Target Shares within the specified thirty (30)-day period, the First Refusal Right shall continue to be applicable to any subsequent disposition of the Target Shares by owner until such right lapses.

 5. Partial Exercise of the First Refusal Right. In the event the Corporation makes a timely
exercise of the First Refusal Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, the owner shall have the option, exercisable by written notice to the Corporation delivered within five
(5) business days after the owner’s receipt of the Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives: 

(i) sale or other disposition of all the Target Shares to the third-party offeror identified in the Disposition
Notice, but in full compliance with the requirements of Paragraph D.4, as if the Corporation did not exercise the First Refusal Right; or 

(ii) sale to the Corporation of the portion of the Target Shares which the Corporation has elected to purchase,
such sale to be effected in conformity with the provisions of Paragraph D.3. The First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses. 

The owner’s failure to deliver timely notification to the Corporation shall be deemed to be an election by owner to sell
the Target Shares pursuant to alternative (i) above. 
 6. Scope. Any new, substituted or
additional securities or other property distributed for any reason with respect to the Purchased Shares shall be immediately subject to the First Refusal Right, but only to the extent the Purchased Shares are at the time covered by such right.

 7. Lapse. The First Refusal Right shall lapse upon the earliest to occur of (i) the first
date on which shares of the Common Stock are held of record by more than five hundred (500) persons, (ii) a determination is made by the Board that a public market exists for the outstanding shares of Common Stock or (iii) a firm
commitment underwritten public offering, pursuant to an effective registration statement under the 1933 Act, covering the offer and sale of the Common Stock in the aggregate amount of at least twenty-five million dollars ($25,000,000). However, the
Market Stand-Off shall continue to remain in full force and effect following the lapse of the First Refusal Right. 

  
 -5- 

	 E.
	 GENERAL PROVISIONS 

1. Assignment. The Corporation may assign the First Refusal Right to any person or entity, including
(without limitation) one or more stockholders of the Corporation. 
 2. No Employment or Service
Contract. Nothing in this Agreement or in the Plan shall confer upon Optionee any right to continue in service for any period of specific duration or interfere with or otherwise restrict rights, if any, of the Corporation (or any Affiliate)
or of Optionee otherwise to terminate Optionee’s service at any time for any reason, with or without cause. 

3. Notices. Any notice required to be given under this Agreement shall be in writing and shall be deemed
effective upon personal delivery or upon deposit in the U.S. mail, registered or certified, postage prepaid and properly addressed to the party entitled to such notice at the address indicated below such party’s signature line on this Agreement
or at such other address as such party may designate by ten (10) days advance written notice under this paragraph to all other parties to this Agreement. 

4. No Waiver. The failure of the Corporation in any instance to exercise the First Refusal Right shall not
constitute a waiver of any other rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Corporation and Optionee. No waiver of any breach or condition of this Agreement shall be
deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature. 
 5.
Cancellation of Shares. If the Corporation shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Purchased Shares to be repurchased in accordance with the
provisions of this Agreement, then from and after such time, the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the right to receive payment of such consideration in
accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Corporation shall be deemed the owner and holder of such shares, whether or not the certificates therefor have been
delivered as required by this Agreement. 
  

	 F.
	 MISCELLANEOUS PROVISIONS 

1. Optionee Undertaking. Optionee hereby agrees to take whatever additional action and execute whatever
additional documents the Corporation may deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on either Optionee or the Purchased Shares pursuant to the provisions of this Agreement.

 2. Agreement is Entire Contract. This Agreement constitutes the entire contract between the
parties hereto with regard to the subject matter hereof. This Agreement is made pursuant to the provisions of the Plan and shall in all respects be construed in conformity with the terms of the Plan. 

  
 -6- 

 3. Governing Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of California without resort to that State’s conflict-of-laws rules requiring application of the law of another jurisdiction. 

4. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an
original, but all of which together shall constitute one and the same instrument. 
 5. Successors and
Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and upon Optionee, Optionee’s permitted assigns and the legal representatives, heirs and
legatees of Optionee’s estate, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join herein and be bound by the terms hereof. 

  
 -7- 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the date and year first
indicated above. 
  

			
	 ONCOLOGIC, INC.

		
	 By:
	 	  

		
	 Title:
	 	  

			
		
	 Address:
	 	  

		 	  

  

			
	  

	 OPTIONEE

		
	 Address:
	 	  

		 	  

 [Signature page for Oncologic, Inc. Stock Purchase Agreement – 1 of 1] 

  
 -8- 

 SPOUSAL ACKNOWLEDGEMENT 

The undersigned spouse of Optionee has read and hereby approves the foregoing Stock Purchase Agreement. In consideration of the
Corporation’s granting Optionee the right to acquire the Purchased Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement. 

 

			
	  

	 OPTIONEE’S SPOUSE

		
	 Address:
	 	  

		 	  

 [Signature page for Oncologic, Inc. Spousal Acknowledgement for Stock Purchase Agreement – 1 of 1]

  
 -9-EX-10.3

 Exhibit 10.3 

TRITON BIOSYSTEMS, INC. 

2001 EQUITY INCENTIVE PLAN 

SECTION 1. Purpose; Definitions. The purposes of the Triton BioSystems, Inc. 2001 Equity Incentive Plan (the “Plan”)
are to: (a) assist Triton BioSystems, Inc., a Delaware corporation (the “Company”), and its affiliated companies in recruiting and retaining highly qualified employees, directors and consultants; (b) provide those employees,
directors and consultants with an incentive for productivity; and (c) provide those employees, directors and consultants with an opportunity to share in the growth and value of the Company. 

For purposes of the Plan, the following initially capitalized words and phrases will be defined as set forth below, unless the context clearly
requires a different meaning: 
 a. “Affiliate” means, with respect to a person or entity, a person that directly or
indirectly controls, or is controlled by, or is under common control with such person or entity; provided, however, that a Newco, as defined herein, shall not be considered an Affiliate of the Company for purposes of this Plan. 

b. “Award” means a grant of Options or Restricted Shares pursuant to the provisions of this Plan. 

c. “Award Agreement” means, with respect to any particular Award, the written document that sets forth the terms of that
particular Award. 
 d. “Board” means the Board of Directors of the Company, as constituted from time to time; provided,
however, that if the Board appoints a Committee to perform some or all of the Board’s administrative functions hereunder pursuant to Section 2, references in this Plan to the “Board” will be deemed to also refer to
that Committee in connection with administrative matters to be performed by that Committee. 
 e. “Cause” exists when the
Participant (as determined by the Board of the Company, Newco or Affiliate for which the Participant then provides services, in its sole discretion): 

(i) engages in any type of disloyalty to the Company, Newco or Affiliate for which the Participant then provides services, including without
limitation, fraud, embezzlement, theft, or dishonesty in the course of his employment or engagement, or otherwise breaches any fiduciary duty owed to that company; 

(ii) is convicted of a felony or a misdemeanor involving moral turpitude; 

(iii) enters a plea of guilty or nolo contendere to a felony or a misdemeanor involving moral turpitude; 

(iv) discloses any confidential, proprietary, business or technical information or trade secret of the Company, a Newco or an Affiliate; or

 (v) breaches any agreement with or duty to the Company, Newco or Affiliate for which the Participant then provides services, including
an agreement which prohibits competition with the Company, a Newco or an Affiliate, or the solicitation of any employees of the Company, a Newco or an Affiliate. 

f. “Change in Control” means (i) the sale, transfer, assignment or other disposition (including by merger or
consolidation, but excluding an underwritten public offering of the common stock of the Company) by stockholders of the Company, in one transaction or a series of related transactions, of more than fifty percent (50%) of the voting power
represented by the then outstanding common stock of the Company to one or more Persons (other than to Persons who are shareholders of the Company on the date that this Plan is adopted by the Board, or to Affiliates of any such shareholders),
(ii) the sale of substantially all the assets of the Company, or (iii) the liquidation or dissolution of the Company. Notwithstanding the foregoing, a transaction will not constitute a Change in Control if its

 
sole purpose is to create a holding company that will be owned in substantially the same proportions by the Persons who held the Company’s securities immediately before such transaction.

 g. “Code” means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto. 

h. “Committee” will mean a committee appointed by the Board in accordance with Section 2 of this Plan. 

i. “Director” means a member of the Board. 

j. “Disability” means a disability which renders a Participant unable to perform the full extent of his duties and
responsibilities to the Company, Newco or Affiliate for which he then provides services, by reason of his illness or incapacity which would entitle him to receive Social Security Income under the Social Security Act, as amended, and the regulations
promulgated thereunder. “Disabled” will mean having a Disability. The determination of whether a Participant is Disabled will be made by the Board of the Company, Newco or Affiliate for which the Participant then provides services, and
such determination will be conclusive; provided, however, that if a Participant is bound by the terms of an employment or consulting agreement between the Participant and that Company, whether the Participant is “Disabled” for purposes of
the Plan will be determined in accordance with the procedures set forth in said employment agreement, if such procedures are therein provided. 

k. “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

l. “Fair Market Value” means, as of any date: (i) if the Shares are not listed or admitted to unlisted trading
privileges on a nationally recognized stock exchange, the value of such Shares on that date, as determined by the Board in its sole and absolute discretion; or (ii) if the Shares are listed or admitted to unlisted trading privileges on a
nationally recognized stock exchange, the closing price of the Shares as reported on the principal nationally recognized stock exchange on which the Shares are traded on such date, or if no Share prices are reported on such date, the closing price
of the Shares on the next preceding date on which there were reported Share prices. 
 m. “Incentive Stock Option” means
any Option intended to be and designated as an “Incentive Stock Option” within the meaning of Section 422 of the Code. 
 n.
“Newco” means Elecon, Inc., Sensera, Inc. or Triton Systems, Inc. 
 o.
“Non-Employee Director” will have the meaning set forth in Rule 16b-3(b)(3)(i) promulgated by the Securities and Exchange Commission under the Exchange
Act, or any successor definition adopted by the Securities and Exchange Commission; provided, however, that the Board or the Committee may, to the extent that it deems necessary to comply with Section 162(m) of the Code or regulations
thereunder, require that each “Non-Employee Director” also be an “outside director” as that term is defined in regulations under Section 162(m). 

p. “Non-Qualified Stock Option” means any Option that is not an Incentive Stock
Option. 
 q. “Option” means any option to purchase Shares (including Restricted Shares, if the Committee so determines)
granted pursuant to Section 5 hereof. 
 r. “Participant” means an individual to whom an Award is granted
pursuant to the eligibility requirements of Section 4. 
 s. “Person” means an individual, partnership,
corporation, limited liability company, trust, joint venture, unincorporated association, or other entity or association. 

  
 - 2 - 

 t. “Restricted Shares” means Shares that are subject to restrictions pursuant to
Section 7 hereof. 
 u. “Share” means a share of the common stock of the Company, subject to substitution or
adjustment as provided in Section 3(c) hereof. 
 v. “Subsidiary” means, in respect of the Company, a
subsidiary company, whether now or hereafter existing, as defined in Sections 424(f) and (g) of the Code. 
 SECTION 2.
Administration. 
 The Plan will be administered by the Board; provided, however, that the Board may at any time appoint a Committee to
perform some or all of the Board’s administrative functions hereunder; and provided further, that the authority of any Committee appointed pursuant to this Section 2 will be subject to such terms and conditions as the Board
may prescribe and will be coextensive with, and not in lieu of, the authority of the Board hereunder. 
 Any Committee established under
this Section 2 will be composed of not fewer than two members, each of whom will serve for such period of time as the Board determines; provided, however, that if the Company has a class of securities required to be registered
under Section 12 of the Securities Exchange Act of 1934, all members of any Committee established pursuant to this Section 2 will be Non-Employee Directors. From time to time the Board may
increase the size of the Committee and appoint additional members thereto, remove members (with or without cause) and appoint new members in substitution therefor, fill vacancies however caused, or remove all members of the Committee and thereafter
directly administer the Plan. 
 Members of the Board who are eligible for Awards or have received Awards may vote on any matters affecting
the administration of the Plan or the grant of Awards, except that no such member will act upon the grant of an Award to himself or herself, but any such member may be counted in determining the existence of a quorum at any meeting of the Board
during which action is taken with respect to the grant of Awards to himself or herself. 
 The Board will have full authority to grant
Awards under this Plan. In particular, the Board will have the authority: 
 a. to select the persons to whom Awards may from time to time
be granted hereunder (consistent with the eligibility conditions set forth in Section 4); 
 b. to determine the type of Award
to be granted to any person hereunder; 
 c. to determine the number of Shares, if any, to be covered by each such Award; 

d. to establish the terms and conditions of each Award Agreement; 

e. to determine whether and under what circumstances an Option may be exercised without a payment of cash under Section 5(d); and

 f. to determine whether, to what extent and under what circumstances Shares and other amounts payable with respect to an Award may be
deferred either automatically or at the election of the Participant. 
 The Board will have the authority to adopt, alter and repeal such
administrative rules, guidelines and practices governing the Plan as it, from time to time, deems advisable; to interpret the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement); to amend the terms of any
Award Agreement, provided that the Participant consents to such amendment; and to otherwise supervise the administration of the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award in
the manner and to the extent it deems necessary to carry out the intent of the Plan. 

  
 - 3 - 

 All decisions made by the Board pursuant to the provisions of the Plan will be final and binding
on all persons, including the Company and Participants. No member of the Board will be liable for any good faith determination, act or omission in connection with the Plan or any Award. 

SECTION 3. Shares Subject to the Plan. 

a. Shares Subject to the Plan. The Shares to be subject to Options or Restricted Shares under the Plan will be authorized and unissued
Shares of the Company, whether or not previously issued and subsequently acquired by the Company. The maximum number of Shares that may be subject to Options or Restricted Shares under the Plan is 7,000,000 and the Company will reserve for the
purposes of the Plan, out of its authorized and unissued Shares, such number of Shares. Notwithstanding the foregoing, no individual will receive, in any calendar year, Awards for more than an aggregate of 7,000,000 Shares. 

b. Effect of the Expiration or Termination of Awards. If and to the extent that an Option expires, terminates or is canceled or
forfeited for any reason without having been exercised in full, the Shares associated with that Option will again become available for grant under the Plan. Similarly, if and to the extent that any Restricted Share is canceled, repurchased or
forfeited for any reason, that Share will again become available for grant under the Plan. 
 c. Other Adjustment. In the event of
any merger, reorganization, consolidation, recapitalization, stock distribution or dividend, stock split or combination, or other change in entity structure affecting the Shares, substitutions or adjustments may be made to the aggregate number, type
and issuer of the securities reserved for issuance under the Plan, in the number and exercise price of outstanding Options, as may be determined to be appropriate by the Board, in its sole and absolute discretion. 

d. Change in Control. Notwithstanding anything to the contrary set forth in the Plan, upon or in anticipation of a Change in Control,
the Board will, in its sole and absolute discretion, and contingent upon the occurrence of that Change in Control, take any one or more of the following actions with respect to each outstanding Award (whether or not vested or forfeitable, in the
case of an Option or Restricted Shares): (i) cause an Option to become fully vested and immediately exercisable; (ii) cause Restricted Shares to become non-forfeitable; (iii) cancel an Option in exchange for an option to purchase
common stock of any successor company; (iv) substitute Restricted Shares in exchange for restricted stock of any successor company; (v) cancel an Option in exchange for cash and/or other substitute consideration with a value equal to the
difference between the Option exercise price and the Fair Market Value per Share on the date of such Change in Control; or (vi) redeem Restricted Shares in exchange for cash and/or other substitute consideration. 

SECTION 4. Eligibility. Employees, directors, consultants, and other individuals who provide services to the Company, a Newco or
any Affiliate are eligible to be granted awards under the Plan. Persons who are not employees of the Company or a Subsidiary are eligible to be granted Awards, but are not eligible to be granted Incentive Stock Options. 

SECTION 5. Options. Options granted under the Plan may be of two types: (i) Incentive Stock Options or (ii) Non-Qualified Stock Options. Options may be granted alone or in addition to other Awards. Any Option granted under the Plan will be in such form as the Board may from time to time approve. 

The Award Agreement evidencing any Option will incorporate the following terms and conditions and will contain such additional terms and
conditions, not inconsistent with the terms of the Plan, as the Board deems appropriate in its sole and absolute discretion: 
 a. Option
Price. The exercise price per Share purchasable under a Non-Qualified Stock Option will be determined by the Board. The exercise price per Share purchasable under an Incentive Stock Option will be not less
than 100% of the Fair Market Value of the Share on the date of the grant. However, any Incentive Stock Option granted to any Participant who, at the time the Option is granted, owns more than 10% of the voting

  
 - 4 - 

 
power of all classes of shares of the Company or of a Subsidiary will have an exercise price per Share of not less than 110% of Fair Market Value per Share on the date of the grant. 

b. Option Term. The term of each Option will be fixed by the Board, but no Option will be exercisable more than ten (10) years
after the date the Option is granted. However, any Incentive Stock Option granted to any Participant who, at the time such Option is granted, owns more than 10% of the voting power of all classes of shares of the Company or of a Subsidiary may not
have a term of more than five (5) years. No Option may be exercised by any person after expiration of the term of the Option. 
 c.
Exercisability. Options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Board at the time of grant. If the Board provides, in its discretion, that any Option is exercisable only
in installments, the Board may waive such installment exercise provisions at any time at or after grant, in whole or in part, based on such factors as the Board determines, in its sole and absolute discretion. 

d. Method of Exercise. Subject to the exercise provisions under Section 5(c) and the termination provisions set forth in
Section 6, Options may be exercised in whole or in part at any time and from time to time during the term of the Option, by giving written notice of exercise to the Company specifying the number of Shares to be purchased. 

(i) Such notice will be accompanied by payment in full of the purchase price, either by certified or bank check, or such other means as the
Board may accept. 
 (ii) As determined by the Board, in its sole discretion, at or after grant, payment in full or in part of the exercise
price of an Option may be made in the form of previously acquired Shares; provided, however, that, in the case of an Incentive Stock Option, the right to make a payment in the form of previously acquired Shares may be authorized only at the
time the Option is granted. 
 (iii) If the Board determines that payment may be made in the form of previously acquired Shares, then, at
the election of the Participant, the purchase price for any or all of the Shares to be acquired may be paid by: (A) surrender of Shares held by or for the account of the Participant with a Fair Market Value per Share, as of the exercise date,
equal to the purchase price multiplied by the number of Shares to be purchased, or (B) the surrender of any exercisable but unexercised portion of the Option having an Option Spread (as defined below) equal to the purchase price multiplied by
the number of Shares to be purchased. The “Option Spread” of a surrendered portion of the Option means, as of the exercise date, an amount equal to the excess of the total Fair Market Value of the Shares underlying the surrendered portion
of the Option over the total exercise price of the Shares underlying the surrendered portion of the Option. 
 (iv) No Shares will be
issued upon exercise of an Option until full payment therefor has been made. A Participant will not have the right to distributions or dividends or any other rights of a shareholder with respect to Shares subject to the Option until the issuance (as
evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company) of the share certificate(s) evidencing the Shares that are being issued upon exercise of the Option. 

e. Incentive Stock Option Limitations. In the case of an Incentive Stock Option, the aggregate Fair Market Value (determined as of the
time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year under the Plan and/or any other plan of the Company or any Subsidiary will not exceed $100,000.
For purposes of applying the foregoing limitation, Incentive Stock Options will be taken into account in the order granted. Any Option not meeting such limitation will be treated for all purposes as a
Non-Qualified Stock Option. 
 f. Termination of Employment. Unless otherwise specified in
the Award Agreement, Options will be subject to the terms of Section 6 with respect to exercise upon termination of employment. 

  
 - 5 - 

 SECTION 6. Termination of Service. Unless otherwise specified with respect to a
particular Award, Options granted hereunder will remain exercisable after termination of service only to the extent specified in this Section 6; provided, however, that if the Participant’s termination of service with the
Company or a Newco is followed by his contiguous engagement by a Newco or the Company, such termination shall not be treated as a termination of service for purposes of this Section 6.  

a. Termination by Reason of Death. If a Participant’s service with the Company, a Newco or any Affiliate terminates by reason of
death, any Option held by such Participant may thereafter be exercised, to the extent then exercisable or on such accelerated basis as the Board may determine, at or after grant, by the legal representative of the estate or by the legatee of the
Participant under the will of the Participant, for a period expiring (i) at such time as may be specified by the Board at or after the time of grant, or (ii) if not specified by the Board, then one (1) year from the date of death, or
(iii) if sooner than the applicable period specified under (i) or (ii) above, then upon the expiration of the stated term of such Option. 

b. Termination by Reason of Disability. If a Participant’s service with the Company, a Newco or any Affiliate terminates by reason
of Disability, any Option held by such Participant may thereafter be exercised by the Participant or his personal representative, to the extent it was exercisable at the time of termination, or on such accelerated basis as the Board may determinate
at or after grant, for a period expiring (i) at such time as may be specified by the Board at or after the time of grant, or (ii) if not specified by the Board, then twelve (12) months from the date of termination of service, or
(iii) if sooner than the applicable period specified under (i) or (ii) about, then upon the expiration of the stated term of such Option. 

c. Cause. If a Participant’s service with the Company, a Newco or any Affiliate is terminated for Cause: (i) any Option not
already exercised will be immediately and automatically forfeited as of the date of such termination, and (ii) any Shares for which the Company has not yet delivered share certificates will be immediately and automatically forfeited and the
Company will refund to the Participant the Option exercise price paid for such Shares, if any. 
 d. Other Termination. If a
Participant’s service with the Company, a Newco or any Affiliate terminates for any reason other than death, Disability or Cause, any Option held by such Participant may thereafter be exercised by the Participant, to the extent it was
exercisable at the time of such termination, or on such accelerated basis as the Board may determine at or after grant, for a period expiring (i) at such time as may be specified by the Board at or after the time of grant, or (ii) if not
specified by the Board, then 90 days from the date of termination of service, or (iii) if sooner than the applicable period specified under (i) or (ii) above, then upon the expiration of the stated term of such Option. 

SECTION 7. Restricted Shares. 

a. Issuance. Restricted Shares may be issued either alone or in conjunction with other Awards. The Board will determine the time or
times within which Restricted Shares may be subject to forfeiture, and all other conditions of such Awards. 
 b. Awards. The Award
Agreement evidencing the grant of any Restricted Shares will contain such terms and conditions, not inconsistent with the terms of the Plan, as the Board deems appropriate in its sole and absolute discretion. The prospective recipient of an Award of
Restricted Shares will not have any rights with respect to such Award, unless and until such recipient has executed an Award Agreement and has delivered a fully executed copy thereof to the Company, and has otherwise complied with the applicable
terms and conditions of such Award. The purchase price for Restricted Shares may, but need not, be zero. 
 c. Certificates. A share
certificate will be issued in connection with each Award of Restricted Shares. Such certificate will be registered on the Company’s books in the name of the Participant receiving the Award, and will bear the following legend as well as any
other legend required by this Plan, the Award Agreement, the Company’s shareholders’ agreement, or by applicable law: 

  
 - 6 - 

 THE TRANSFERABILITY OF THIS CERTIFICATE AND THE SHARES REPRESENTED HEREBY ARE SUBJECT TO THE
TERMS AND CONDITIONS (INCLUDING FORFEITURE) OF THE TRITON BIOSYSTEMS, INC. 2001 EQUITY INCENTIVE PLAN AND AN AGREEMENT ENTERED INTO BETWEEN THE REGISTERED OWNER AND TRITON BIOSYSTEMS, INC. COPIES OF SUCH PLAN AND AGREEMENT ARE ON FILE IN THE
PRINCIPAL OFFICES OF TRITON BIOSYSTEMS, INC. AND WILL BE MADE AVAILABLE TO ANY SHAREHOLDER WITHOUT CHARGE UPON REQUEST TO THE SECRETARY OF THE COMPANY. 

Share certificates evidencing Restricted Shares be held in custody by the Company or in escrow by an Escrow Agent until the restrictions
thereon have lapsed, and that, as a condition of any Restricted Share Award, the Participant deliver to the Company a share power, endorsed in blank, relating to the Shares covered by such Award. 

d. Restrictions and Conditions. The Restricted Shares awarded pursuant to this Section 7 will be subject to the following
restrictions and conditions: 
 (i) During a period commencing with the date of grant of an Award of Restricted Shares and ending at such
time or times as specified by the Board (the “Restriction Period”), the Participant will not be permitted to sell, transfer, pledge, assign or otherwise encumber Restricted Shares awarded under the Plan. The Board may condition the
lapse restrictions on Restricted Shares upon the continued employment or service of the recipient with the Company, a Newco or an Affiliate, the attainment of specified individual or corporate performance goals, or such other factors as the Board
may determine, in its sole and absolute discretion. 
 (ii) Prior to the expiration of the Restriction Period, the Participant will not be
entitled to receive any cash distributions or dividends paid with respect to Restricted Shares and will not be entitled to vote such Restricted Shares. A Participant will be entitled to receive any distributions or dividends paid in the form of
securities with respect to Restricted Shares, but such securities will be subject to the same terms and conditions as the Restricted Shares with respect to which they were paid, including, without limitation, the same Restriction Period. 

(iii) Subject to the applicable provisions of the Award Agreement, if a Participant’s service with the Company, Newco or Affiliate
terminates prior to the expiration of the Restriction Period for reasons other than death or Disability, all of that Participant’s Restricted Shares which then remain subject to forfeiture will be forfeited. 

(iv) Upon the death or Disability of a Participant during the Restriction Period: 

(A) restrictions based on continued employment or service with the Company, a Newco or an Affiliate will lapse with respect to a percentage
of the Restricted Shares granted to the Participant that is equal to the percentage of the Restriction Period that has elapsed as of the date of death or the date on which such Disability commenced (as determined by the Board of the Company, Newco
or Affiliate for which the Participant then provided services, in its sole discretion), and 
 (B) restrictions based on individual or
corporate performance will lapse to the extent determined by the Board in its sole discretion. 
 (v) In the event of hardship or other
special circumstances of a Participant whose service with the Company, Newco or Affiliate is involuntarily terminated (other than for Cause), the Board may, in its sole discretion, waive in whole or in part any or all remaining restrictions with
respect to such Participant’s Restricted Shares, based on such factors as the Board may deem appropriate. 
 (vi) If and when the
Restriction Period expires without a prior forfeiture of the Restricted Shares subject to such Restriction Period (or if and when the restrictions applicable to Restricted Shares 

  
 - 7 - 

 
lapse pursuant to Sections 3(d), 7(d)(iv) or 7(d)(v)), the certificates for such Shares will be replaced with new certificates, without the restrictive legend described in
Section 7(c), and such new certificates will be promptly delivered to the Participant, the Participant’s representative (if the Participant has suffered a Disability), or the Participant’s estate or heir (if the Participant has
died). 
 (vii) Notwithstanding the foregoing, if the Participant’s termination of service with the Company or a Newco is followed by
his contiguous engagement by a Newco or the Company, such termination shall not be treated as a termination of service for purposes of this Section 7. 

SECTION 8. Amendments and Termination. The Board may amend, alter or discontinue the Plan at any time, but,
except as otherwise provided in Section 3(d) of the Plan, no amendment, alteration or discontinuation will be made which would impair the rights of a Participant with respect to an Award that is outstanding under the Plan, without the
Participant’s consent, or which, without the approval of such amendment by the Company’s shareholders (pursuant to its by-laws and the Delaware General Corporation Law) within one year (365 days) of its adoption by the Board, would:
(i) increase the total number of Shares reserved for the purposes of the Plan (except as otherwise provided in Section 3(c)), or (ii) change the persons or class of persons eligible to receive Awards. 

SECTION 9. Unfunded Status of Plan. The Plan is intended to be “unfunded.” With respect to any payments not yet made
to a Participant by the Company, nothing contained herein will give any such Participant any rights that are greater than those of a general creditor of the Company. In its sole discretion, the Board may authorize the creation of grantor trusts or
other arrangements to meet the obligations created under the Plan to deliver Shares or payments in lieu of Shares or with respect to other Awards hereunder. 

SECTION 10. General Provisions. 

a. The Board may require each Participant to represent to and agree with the Company in writing that the Participant is acquiring securities
of the Company for investment purposes and without a view to distribution thereof and as to such other matters as the Board believes are appropriate. The certificate evidencing any Award and any securities issued pursuant thereto may include any
legend which the Board deems appropriate to reflect any restrictions on transfer and compliance with securities laws. 
 All certificates
for Shares or other securities delivered under the Plan will be subject to such share-transfer orders and other restrictions as the Board may deem advisable under the rules, regulations, and other requirements
of the Securities Act of 1933, as amended, the Exchange Act, any stock exchange upon which the Shares are then listed, and any other applicable Federal or state securities laws, and the Board may cause a legend or legends to be put on any such
certificates to make appropriate reference to such restrictions. 
 b. Nothing contained in the Plan will prevent the Board from adopting
other or additional compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 

c. Neither the Company’s adoption of the Plan nor the granting of an Award hereunder will confer upon any employee of the Company, a
Newco or an Affiliate the right to continued employment or engagement, nor will it interfere in any way with the right of that company to terminate the employment of any of its employees at any time. 

d. No later than the date as of which an amount first becomes includible in the gross income of the Participant for Federal income tax
purposes with respect to any Award under the Plan, the Participant will pay to the Company, or make arrangements satisfactory to the Board regarding the payment of, any Federal, state or local taxes of any kind required by law to be withheld with
respect to such amount. Unless otherwise determined by the Board, the minimum required withholding obligations may be settled with Shares, including Shares that are part of the Award that gives rise to the withholding requirement. The obligations of
the Company under the Plan will be 

  
 - 8 - 

 
conditioned on such payment or arrangements and the Company will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the
Participant. 
 e. The Board will establish such procedures as it deems appropriate for a Participant to designate a beneficiary to whom any
amounts payable in the event of the Participant’s death are to be paid. 
 f. Except as may otherwise be specifically determined by the
Board with respect to a particular Award, no Award will be transferable by the Participant otherwise than by will or by the laws of descent and distribution, and all Awards will be exercisable, during the Participant’s lifetime, only by the
Participant or, in the event of his Disability, by his personal representative. 
 SECTION 11. Effective Date of Plan. This
Plan will become effective on the date that it is approved by a majority of the votes cast at a duly held shareholder meeting at which a quorum representing a majority of Company’s outstanding voting shares is present, either in person or by
proxy. 
 SECTION 12. Term of Plan. This Plan will continue in effect until terminated in accordance with Section 8;
provided, however, that no Incentive Stock Option will be granted hereunder on or after the tenth (10th) anniversary of the date of shareholder approval of the Plan; but provided further, that Incentive Stock Options granted prior
to such tenth anniversary may extend beyond that date. 
 SECTION 13. Invalid Provisions. In the event that any provision of
this Plan is found to be invalid or otherwise unenforceable under any applicable law, such invalidity or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such other
provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein. 

SECTION 14. Governing Law. This Plan and all Awards granted hereunder will be governed by and construed in accordance with the
laws and judicial decisions of the State of Delaware, without regard to the application of the principles of conflicts of laws. 

SECTION 15. Board Action. Notwithstanding anything to the contrary set forth in this Plan, any and all actions of the Board or
Committee, as the case may be, taken under or in connection with this Plan and any agreements, instruments, documents, certificates or other writings entered into, executed, granted, issued and/or delivered pursuant to the terms hereof, will be
subject to and limited by any and all votes, consents, approvals, waivers or other actions of all or certain stockholders of the Company or other persons required by: 

a. the Company’s governing documents (as the same may be amended and/or restated from time to time); and 

b. any other agreement, instrument, document or writing now or hereafter existing, between or among the Company and its stockholders or other
persons (as the same may be amended from time to time). 

  
 - 9 - 

 SECTION 16. Notices. Any notice to be given to the Company pursuant to the
provisions of the Plan shall be addressed to the Company in care of its Secretary (or such other person as the Company may designate from time to time) at its principal executive office, and any notice to be given to a Participant shall be delivered
personally or addressed to him or her at the address given beneath his or her signature on his or her Award Agreement, or at such other address as such Participant may hereafter designate in writing to the Company. Any such notice shall be deemed
duly given on the date and at the time delivered via personal, courier or recognized overnight delivery service or, if sent via telecopier, on the date and at the time telecopied with confirmation of delivery or, if mailed, on the date five
(5) days after the date of the mailing (which shall be by regular, registered or certified mail). Delivery of a notice by telecopy (with confirmation) shall be permitted and shall be considered delivery of a notice notwithstanding that it is
not an original that is received. 
 ADOPTION AND APPROVAL OF PLAN 

Date Plan adopted by Board: March 23, 2001 

Date Plan approved by Shareholders: March 23, 2001 

Effective Date of Plan: March 23, 2001 

  
 - 10 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]